Avadel Pharmaceuticals Receives FDA Orphan Drug Designation

An update from Avadel Pharmaceuticals ( (AVDL) ) is now available.

On June 5, 2025, Avadel Pharmaceuticals announced that the FDA granted Orphan Drug Designation to LUMRYZ for the treatment of idiopathic hypersomnia, highlighting its potential clinical superiority and contribution to patient care. This designation supports Avadel’s strategy to develop differentiated therapies for rare sleep disorders and could provide market exclusivity and other benefits, enhancing its position in the industry.

The most recent analyst rating on (AVDL) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.

Spark’s Take on AVDL Stock

According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.

Avadel Pharmaceuticals shows strong growth potential with robust revenue increases and positive sentiment from recent corporate developments. However, significant challenges in achieving profitability, ongoing cash flow issues, and negative valuation metrics weigh on the overall score. The technical indicators suggest moderate bullish momentum, while earnings call optimism and corporate events provide a positive outlook, albeit with caution due to external risks and financial constraints.

To see Spark’s full report on AVDL stock, click here.

More about Avadel Pharmaceuticals

Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to improve the lives of patients, particularly in the area of rare sleep disorders. The company is known for its development of LUMRYZ, a sodium oxybate medication, which is positioned as a once-nightly treatment for conditions like narcolepsy and idiopathic hypersomnia.

Average Trading Volume: 1,101,583

Technical Sentiment Signal: Hold

Current Market Cap: $912.2M

Learn more about AVDL stock on TipRanks’ Stock Analysis page.